Maria Rivas

CIK: 0001755794

Transaction Breakdown

Open Market Buys (P)1 (20.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)2 (40.0%)

Derivative conversions

Awards (A)2 (40.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

TLX

Telix Pharmaceuticals Ltd

Director

COO

COOPER COMPANIES, INC.

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

COO
COOPER COMPANIES, INC.
Apr 1, 2026
Exercise(M)
Direct
3.3K shares-
COO
COOPER COMPANIES, INC.
Apr 1, 2026
Award(A)
Restricted Stock Units
Direct
3.8K shares-
COO
COOPER COMPANIES, INC.
Dec 18, 2025
Purchase(P)
Indirect
1K shares at avg. $82.13$82K
COO
COOPER COMPANIES, INC.
Apr 1, 2025
Exercise(M)
Direct
2.7K shares-
COO
COOPER COMPANIES, INC.
Apr 1, 2025
Award(A)
Restricted Stock Units
Direct
3.3K shares-

		Type	Shares	Price		Ownership
Apr 1, 2026	COO COOPER COMPANIES, INC.	Exercise(M)	3,322	-	$0	Direct
Apr 1, 2026	COO COOPER COMPANIES, INC.	Award(A) Restricted Stock Units	3,779	-	-	Direct
Dec 18, 2025	COO COOPER COMPANIES, INC.	Purchase(P)	1,000	$82.13	$82,130	Indirect
Apr 1, 2025	COO COOPER COMPANIES, INC.	Exercise(M)	2,721	-	-	Direct
Apr 1, 2025	COO COOPER COMPANIES, INC.	Award(A) Restricted Stock Units	3,322	-	-	Direct

1-5 of 5 transactions

About Rivas Maria

Rivas Maria (SEC CIK 0001755794) files insider reports with the SEC as Director of Telix Pharmaceuticals Ltd (TLX) and Director of COOPER COMPANIES, INC. (COO).

Signal8 holds 4 ownership filings by Rivas Maria (1 Form 3, 3 Form 4), filed between Apr 3, 2025 and May 18, 2026. Those filings report 5 transactions, from Apr 1, 2025 to Apr 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Rivas Maria's filings is in SAN RAMON, CA.

Recent filings by Rivas Maria

Apr 1, 2026: Option exercise of COO shares (Form 4, code M).
Apr 1, 2026: Grant or award of COO derivative securities (Form 4, code A).
Dec 18, 2025: Open-market purchase of COO shares (Form 4, code P).
Apr 1, 2025: Option exercise of COO shares (Form 4, code M).
Apr 1, 2025: Grant or award of COO derivative securities (Form 4, code A).

Other insiders filing for Telix Pharmaceuticals Ltd (TLX)

Smith Darren Charlton, Group Chief Financial Officer
GILL DAVID N, Director
Jellison William R, Director
Behrenbruch Christian, MD & Group CEO
Cade David Norman, Group Chief Medical Officer
Nelson Mark Alexander, Director

How to read Form 4 transaction codes